Sathgen in the News
Latest updates, milestones, and media coverage of our journey in advancing cancer therapeutics.
Godavari Biorefineries Incorporates Sathgen Therapeutics LLC in Princeton, New Jersey
Godavari Biorefineries Limited (GBL) announced the incorporation of a new wholly-owned step-down subsidiary, Sathgen Therapeutics LLC, based in Princeton, New Jersey, USA. This strategic expansion strengthens GBL's clinical-stage biotechnology presence, focusing on global intellectual property out-licensing and accelerating drug-development programs for cancer treatment, particularly targeting breast and prostate cancer.
Godavari Biorefineries shares surged over 11% to ₹300 intraday on Wednesday following the incorporation of a new US subsidiary, Sathgen Therapeutics LLC, in New Jersey. This strategic move aims to bolster the company's clinical-stage biotechnology presence, focusing on global intellectual property out-licensing and accelerating drug development programs. The stock closed 8% higher at ₹290.5, significantly outperforming the BSE Sensex (Source: Whalesbook).
Dr. Padmaja Ganpathy to take over as the CEO and Dr. Sendurai Mani as the Chief Scientific Advisor.
The scientific advisory board includes distinguished experts such as Razelle Kurzrock, an internationally recognized leader in precision oncology, immunotherapy, and early-phase clinical trials, and Massimo Cristofanilli, a global authority in metastatic breast cancer and cancer biology. Their depth of experience will be instrumental as Sathgen advances its portfolio toward U.S. partnerships and the next stages of development.
Our Journey & Milestones
Key moments in Sathgen's mission to develop breakthrough cancer therapeutics.
Company of The Year - Silicon India Magazine
Sathgen gets awarded Company of The Year by Silicon India magazine for their pioneering work in making cancer treatments safer.
Read ArticleFeatured in India Pharma Outlook
Sathgen Therapeutics is Empowering Cancer Treatment & Hope Through Pioneering Advanced Therapies as covered by India Pharma Outlook.
Read ArticleTop 10 Most Promising Drug Discovery Companies - 2023
SiliconIndia magazine recognized us as one of the '10 Most Promising Drug Discovery & Development Companies – 2023' for "Fusing Nature & Science for Breakthrough Anti-Cancer Solutions".
Read ArticlePharma Partnering Summit - Boston
We presented our latest work on clinical development of our anti-cancer and anti-viral molecules at the Pharma Partnering Summit on October 19-20, 2023 in Boston, MA.
First Two Cohorts of Healthy Volunteers Completed
We completed the dosing of the first two cohorts of healthy volunteers with our lead anti-cancer and anti-viral drug, MSP008-22, in a phase 1 clinical trial. No serious adverse events were reported. Covered by news outlets in India, USA, UK, Germany, Spain, France.
Read Press ReleaseFirst Patient Cohort Dosing Completed
We completed the dosing of the first patient cohort with our lead anti-cancer drug, MSP008-22, a phase 1 clinical trial in patients with advanced solid tumors. This milestone was covered as press releases in India, USA, UK, Germany, Spain, France.
Read Press ReleasePharma Partnering Summit - San Diego
We showcased our work on the anti-cancer drugs at the Pharma Partnering Summit in San Diego, CA, USA, a conference that brings together the pharmaceutical and biotech worlds.
Phase I Healthy Volunteer Trial Initiated
The healthy volunteer trial entitled "A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers" was initiated.
First-in-Human Patient Trial Initiated
Our first-in-human patient trial entitled "A Single Ascending Dose, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetic Profile of MSP008-22 in Patients with Advanced Solid Tumors" was initiated.
MSP008-22 Anti-Cancer Compound Patent
Patent for MSP008-22 anti-cancer compound granted in USA and Japan.
Synthesis of Cleistanthin A Patent - Global
Patent for Synthesis of Cleistanthin A and its derivatives granted in India, USA, Germany, Netherlands, France, UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.
Process for Synthesis of Cleistanthin Patent
Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa.